NCT06503250Completed
A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
Effectiveness and Safety of Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization as Conversion Therapy Among Patients With Initially Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice in China
Source: ClinicalTrials.gov · Last updated 21 Mar 2025
Brief summary (registry, in English)
This is a multicenter, retrospective, observational cohort study to describe the effectiveness and safety of Atezo+Bev plus Transarterial Chemoembolization (TACE) among adult patients with unresectable hepatocellular carcinoma (HCC) in real-world clinical practice in China. Eligible patients diagnosed with unresectable HCC initiating the Atezo+Bev and TACE between 28 October 2020 and 31 December 2023 will be included in this study.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 113 (actual)
- First submitted
- 10 Jul 2024
- Start date
- 19 Jul 2024
- Primary completion date
- 27 Nov 2024
- Lead sponsor
- Hoffmann-La Roche
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06503250
What you commit to
- Study type: Observational
- Participants enrolled: 113
- From 19 Jul 2024 to the primary completion date, 27 Nov 2024
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treated with other systemic therapy or resection against HCC
- Diagnosed with concomitant cancer except for basal cell carcinoma
Other illness
- Advanced portal vein tumor thrombosis (PVTT) as defined by: Grade Vp 4, Cheng's Classification Type III or IV, or presence of a tumor thrombus in the main trunk of the portal vein, a portal vein branch contralateral to the primarily involved lobe, or superior mesenteric vein
- China Liver Cancer (CNLC) Stage IIIb, or history of extrahepatic metastasis
Other
- No visit record after initiating both Atezo+Bev and TACE
- Terminal-stage HCC
Who the study is looking for
- Initiating both Atezo+Bev and TACE between 28 October 2020 and 31 December 2023 regardless of sequencing, number of doses/cycles, and type of TACE
- At least one dose of Atezo+Bev and one cycle of TACE spaced no longer than 4 weeks
- Diagnosed with HCC and considered as unresectable by any of the below criteria:
- Predicted insufficient future liver remnant volume (FLRV) after liver resection, OR
- Predicted unattainable safe negative tumor margin resection, i.e., R0 resection, OR
- "Unresectable" directly documented in the medical records
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Third Affiliated Hospital of Sun Yat-Sen University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| the First Affiliated Hospital of Sun Yat-sen University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| Zhongshan Hospital,Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Tianjin First Central Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
| The First Affiliated Hospital of Xian Jiao Tong University Coordinator of this site? Confirm its status | Xi'an | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.